Rhumbline Advisers Alaunos Therapeutics, Inc. Transaction History

Rhumbline Advisers

$105 Billion
Q2 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$0.43 - $0.65 $2,737 - $4,137	6,366 New	6,366 $3,000
Q2 2022 Aug 11, 2022	SELL	$0.41 - $1.24 $89,780 - $271,532	-218,978 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$0.62 - $1.17 $940 - $1,774	-1,517 Reduced 0.69%	218,978 $143,000
Q4 2021 Feb 10, 2022	SELL	$1.09 - $1.89 $4,811 - $8,342	-4,414 Reduced 1.96%	220,495 $240,000
Q3 2021 Nov 12, 2021	BUY	$1.44 - $2.73 $9,056 - $17,168	6,289 Added 2.88%	224,909 $409,000
Q2 2021 Aug 05, 2021	SELL	$2.63 - $3.67 $144,258 - $201,303	-54,851 Reduced 20.06%	218,620 $577,000
Q1 2021 May 06, 2021	SELL	$2.82 - $5.6 $61,532 - $122,191	-21,820 Reduced 7.39%	273,471 $984,000
Q4 2020 Feb 10, 2021	BUY	$2.09 - $3.09 $60,862 - $89,983	29,121 Added 10.94%	295,291 $744,000
Q3 2020 Nov 12, 2020	SELL	$2.39 - $3.43 $102,416 - $146,982	-42,852 Reduced 13.87%	266,170 $671,000
Q2 2020 Aug 13, 2020	BUY	$2.2 - $3.71 $233,173 - $393,215	105,988 Added 52.2%	309,022 $1.01 Million
Q1 2020 May 06, 2020	SELL	$1.9 - $4.98 $4,922 - $12,903	-2,591 Reduced 1.26%	203,034 $497,000
Q4 2019 Feb 05, 2020	BUY	$3.95 - $5.35 $12,813 - $17,355	3,244 Added 1.6%	205,625 $971,000
Q3 2019 Oct 23, 2019	SELL	$4.13 - $6.94 $5,616 - $9,438	-1,360 Reduced 0.67%	202,381 $866,000
Q2 2019 Aug 14, 2019	BUY	$3.98 - $6.2 $122,568 - $190,935	30,796 Added 17.81%	203,741 $1.19 Million
Q1 2019 May 01, 2019	SELL	$2.0 - $4.4 $4,270 - $9,394	-2,135 Reduced 1.22%	172,945 $666,000
Q4 2018 Jan 31, 2019	BUY	$1.61 - $3.62 $89,482 - $201,195	55,579 Added 46.51%	175,080 $327,000
Q3 2018 Nov 07, 2018	SELL	$2.26 - $3.27 $21,128 - $30,571	-9,349 Reduced 7.26%	119,501 $382,000
Q2 2018 Aug 06, 2018	BUY	$3.02 - $4.94 $10,693 - $17,492	3,541 Added 2.83%	128,850 $389,000
Q1 2018 May 02, 2018	SELL	$3.46 - $5.14 $14,618 - $21,716	-4,225 Reduced 3.26%	125,309 $491,000
Q4 2017 Feb 09, 2018	SELL	$4.0 - $6.54 $93,888 - $153,506	-23,472 Reduced 15.34%	129,534 $536,000
Q3 2017 Nov 06, 2017	BUY	$4.99 - $6.57 $763,499 - $1.01 Million	153,006	153,006 $939,000

Others Institutions Holding TCRT

# of Institutions

Shares Held

92.6K

Call Options Held

Put Options Held

View Full List

About Alaunos Therapeutics, Inc.

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $458M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

More about TCRT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account